158 related articles for article (PubMed ID: 35822492)
1. Promising disruptors of p53-MDM2 dimerization from some medicinal plant phytochemicals: a molecular modeling study.
Oyedele AK; Adelusi TI; Ogunlana AT; Ayoola MA; Adeyemi RO; Babalola MO; Ayorinde JB; Isong JA; Ajasa TO; Boyenle ID
J Biomol Struct Dyn; 2023; 41(12):5817-5826. PubMed ID: 35822492
[TBL] [Abstract][Full Text] [Related]
2. Integrated virtual screening and molecular dynamics simulation revealed promising drug candidates of p53-MDM2 interaction.
Oyedele AK; Adelusi TI; Ogunlana AT; Adeyemi RO; Atanda OE; Babalola MO; Ashiru MA; Ayoola IJ; Boyenle ID
J Mol Model; 2022 May; 28(6):142. PubMed ID: 35536362
[TBL] [Abstract][Full Text] [Related]
3. Targeting p53-MDM2 interactions to identify small molecule inhibitors for cancer therapy: beyond "Failure to rescue".
Chukwuemeka PO; Umar HI; Iwaloye O; Oretade OM; Olowosoke CB; Elabiyi MO; Igbe FO; Oretade OJ; Eigbe JO; Adeojo FJ
J Biomol Struct Dyn; 2022; 40(19):9158-9176. PubMed ID: 33988074
[TBL] [Abstract][Full Text] [Related]
4. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
5. Screening of medicinal plant phytochemicals as natural antagonists of p53-MDM2 interaction to reactivate p53 functioning.
Riaz M; Ashfaq UA; Qasim M; Yasmeen E; Ul Qamar MT; Anwar F
Anticancer Drugs; 2017 Oct; 28(9):1032-1038. PubMed ID: 28723868
[TBL] [Abstract][Full Text] [Related]
6. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
[TBL] [Abstract][Full Text] [Related]
7. Group-based QSAR and molecular dynamics mechanistic analysis revealing the mode of action of novel piperidinone derived protein-protein inhibitors of p53-MDM2.
Goyal S; Grover S; Dhanjal JK; Tyagi C; Goyal M; Grover A
J Mol Graph Model; 2014 Jun; 51():64-72. PubMed ID: 24858256
[TBL] [Abstract][Full Text] [Related]
8. An Effective Virtual Screening Protocol To Identify Promising p53-MDM2 Inhibitors.
Tortorella P; Laghezza A; Durante M; Gomez-Monterrey I; Bertamino A; Campiglia P; Loiodice F; Daniele S; Martini C; Agamennone M
J Chem Inf Model; 2016 Jun; 56(6):1216-27. PubMed ID: 27269808
[TBL] [Abstract][Full Text] [Related]
9. Molecular Docking and Molecular Dynamics Studies Reveal the Anticancer Potential of Medicinal-Plant-Derived Lignans as MDM2-P53 Interaction Inhibitors.
Shoaib TH; Abdelmoniem N; Mukhtar RM; Alqhtani AT; Alalawi AL; Alawaji R; Althubyani MS; Mohamed SGA; Mohamed GA; Ibrahim SRM; Hussein HGA; Alzain AA
Molecules; 2023 Sep; 28(18):. PubMed ID: 37764441
[TBL] [Abstract][Full Text] [Related]
10. Dihydropyrimidine derivatives as MDM2 inhibitors.
Mehri A; Mahnam K; Sirous H; Aghaei M; Rafiei L; Rostami M
Chem Biol Drug Des; 2024 Jan; 103(1):e14399. PubMed ID: 38011915
[TBL] [Abstract][Full Text] [Related]
11. An Application of Fit Quality to Screen MDM2/p53 Protein-Protein Interaction Inhibitors.
Xue X; Bao G; Zhang HQ; Zhao NY; Sun Y; Zhang Y; Wang XL
Molecules; 2018 Dec; 23(12):. PubMed ID: 30513790
[No Abstract] [Full Text] [Related]
12. Prospective virtual screening for novel p53-MDM2 inhibitors using ultrafast shape recognition.
Patil SP; Ballester PJ; Kerezsi CR
J Comput Aided Mol Des; 2014 Feb; 28(2):89-97. PubMed ID: 24554192
[TBL] [Abstract][Full Text] [Related]
13. Identification of new inhibitors of Mdm2-p53 interaction via pharmacophore and structure-based virtual screening.
Atatreh N; Ghattas MA; Bardaweel SK; Rawashdeh SA; Sorkhy MA
Drug Des Devel Ther; 2018; 12():3741-3752. PubMed ID: 30464405
[TBL] [Abstract][Full Text] [Related]
14. Protein-peptide molecular docking with large-scale conformational changes: the p53-MDM2 interaction.
Ciemny MP; Debinski A; Paczkowska M; Kolinski A; Kurcinski M; Kmiecik S
Sci Rep; 2016 Dec; 6():37532. PubMed ID: 27905468
[TBL] [Abstract][Full Text] [Related]
15. Structural basis for high-affinity peptide inhibition of p53 interactions with MDM2 and MDMX.
Pazgier M; Liu M; Zou G; Yuan W; Li C; Li C; Li J; Monbo J; Zella D; Tarasov SG; Lu W
Proc Natl Acad Sci U S A; 2009 Mar; 106(12):4665-70. PubMed ID: 19255450
[TBL] [Abstract][Full Text] [Related]
16. Targeting COVID-19 (SARS-CoV-2) main protease through active phytochemicals of ayurvedic medicinal plants -
Shree P; Mishra P; Selvaraj C; Singh SK; Chaube R; Garg N; Tripathi YB
J Biomol Struct Dyn; 2022 Jan; 40(1):190-203. PubMed ID: 32851919
[TBL] [Abstract][Full Text] [Related]
17. Pharmacoinformatics approach for the screening of Kovidra
More-Adate P; Lokhande KB; Shrivastava A; Doiphode S; Nagar S; Singh A; Baheti A
J Biomol Struct Dyn; 2024 May; 42(8):4263-4282. PubMed ID: 37288734
[TBL] [Abstract][Full Text] [Related]
18. Simulation of MDM2 N-terminal domain conformational lability in the presence of imidazoline based inhibitors of MDM2-p53 protein-protein interaction.
Gureev M; Novikova D; Grigoreva T; Vorona S; Garabadzhiu A; Tribulovich V
J Comput Aided Mol Des; 2020 Jan; 34(1):55-70. PubMed ID: 31781989
[TBL] [Abstract][Full Text] [Related]
19. The development of piperidinones as potent MDM2-P53 protein-protein interaction inhibitors for cancer therapy.
Liao G; Yang D; Ma L; Li W; Hu L; Zeng L; Wu P; Duan L; Liu Z
Eur J Med Chem; 2018 Nov; 159():1-9. PubMed ID: 30253242
[TBL] [Abstract][Full Text] [Related]
20. Spiro-oxindoles as a Promising Class of Small Molecule Inhibitors of p53-MDM2 Interaction Useful in Targeted Cancer Therapy.
Gupta AK; Bharadwaj M; Kumar A; Mehrotra R
Top Curr Chem (Cham); 2017 Feb; 375(1):3. PubMed ID: 27943171
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
